BioMarin paints picture of dwarfism drug’s wider efficacy on Phase III win
NDA FilingVoxzogoPositive
AI Analysis
Summary
BioMarin announced positive Phase III results for Voxzogo in hypochondroplasia and filed an NDA with US regulators, demonstrating broader efficacy of the dwarfism treatment beyond its initial indication.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase III positive results led to NDA filing
Importance:8/10
Sentiment:
0.80
rare diseasedwarfismregulatory filingorphan indication
Related Companies
Read the original article
Published by Clinical Trials Arena on September 10, 2026 10:41 AM